Press releases – Nanoform small is powerful

Non Regulatory

December 23, 2020

Nanoform included in Nasdaq First North 25 index as of Jan 4th, 2021

Non Regulatory

December 21, 2020

First dosing of nanoformed drug successfully accomplished

Regulatory

December 17, 2020

Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules

Non Regulatory

December 8, 2020

Notification of major shareholdings according to Nanoform’s Articles of Association

Non Regulatory

December 2, 2020

Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)

Regulatory

November 27, 2020

Nanoform Finland Plc, Interim Report January – September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time

Regulatory

November 27, 2020

Nanoform launches technology for biologics and sets new near-term business target for 2021

Non Regulatory

November 16, 2020

Invitation to presentation of Nanoform’s Q3 Report on November 27

Non Regulatory

November 11, 2020

Nanoform to present at Avanza Börsdag on November 18

Regulatory

October 23, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory

October 20, 2020

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule

Regulatory

September 2, 2020

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade

Regulatory

September 2, 2020

Share subscriptions based on Nanoform Finland Plc’s 2/2019 and 1/2020 Stock Option Programs

Non Regulatory

September 1, 2020

Nanoform expands global commercial team with US appointments

Regulatory

September 1, 2020

Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting and Board of Directors on September 1, 2020

Regulatory

August 28, 2020

NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST

Regulatory

August 6, 2020

Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen

Regulatory

August 6, 2020

Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC

Regulatory

August 6, 2020

Nanoform convenes EGM to elect Cynthia Schwalm as board member

Non Regulatory

July 9, 2020

Nanoform’s positive commercial momentum continues

Regulatory

June 25, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Non Regulatory

June 15, 2020

Nanoform Finland Plc appoints Peter Hänninen as General Counsel

Regulatory

June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Edward Hæggström

Regulatory

June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström

Regulatory

June 10, 2020

Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period

Regulatory

June 10, 2020

Nanoform Finland Oyj:n listautumisannin lisäosakeoption toteuttaminen ja vakauttamisajan päättäminen

Regulatory

June 10, 2020

Utnyttjande av övertilldelningsoptionen i noteringen av Nanoform Finland Plc och avbrytande av stabiliseringsperioden

Regulatory

June 9, 2020

De tio största aktieägarna i Nanoform Finland Plc efter genomförandet av noteringen

Regulatory

June 9, 2020

Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering

Regulatory

June 9, 2020

Nanoform Finland Oyj:n kymmenen suurinta osakkeenomistajaa listautumisannin päättymisen jälkeen

Regulatory

June 3, 2020

Erbjudandet i samband med noteringen av Nanoform har kraftigt övertecknats och kommer att genomföras som planerat – handel i aktierna förväntas inledas imorgon

Regulatory

June 3, 2020

The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow

Regulatory

June 3, 2020

Nanoformin listautumisanti on huomattavasti ylimerkitty ja listautuminen toteutetaan suunnitellusti – osakkeiden kaupankäynnin odotetaan alkavan huomenna

Regulatory

June 2, 2020

The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory

June 2, 2020

Nanoformin Instituutioanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory

June 2, 2020

Det institutionella erbjudandet i Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory

June 1, 2020

Nanoformin Yleisöanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory

June 1, 2020

Erbjudandet i samband med noteringen av Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory

June 1, 2020

Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory

May 28, 2020

Nanoform Finland Plc har ansökt om upptagande till handel av dess aktier på Nasdaq First North Premier Growth Market Finland och Nasdaq First North Premier Growth Market Sweden

Regulatory

May 28, 2020

Nanoform Finland Oyj on hakenut osakkeidensa listausta Nasdaq First North Premier Growth Market Finlandissa ja Nasdaq First North Premier Growth Market Swedenissä

Regulatory

May 28, 2020

Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden

Regulatory

May 25, 2020

Nanoform offentliggör en fast teckningskurs och publicerar ett prospekt för den planerade parallellnoteringen av dess aktier på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory

May 25, 2020

Nanoform julkistaa suunnitellun listautumisantinsa kiinteän merkintähinnan sekä esitteen liittyen kaksoislistautumiseensa Nasdaq First North Premier Growth Market -markkinapaikoille Suomessa ja Ruotsissa

Regulatory

May 25, 2020

Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory

May 11, 2020

Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory

May 11, 2020

Nanoform avser att genomföra ett erbjudande och att parallellnoteras på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory

May 11, 2020

Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille

Non Regulatory

May 4, 2020

Nanoform awarded GMP certification

Non Regulatory

April 9, 2020

Nanoform appoints Miguel Calado as Chairman of the Board

Non Regulatory

March 9, 2020

Nanoform and Orion collaborate on next-generation drug development

Non Regulatory

February 10, 2020

Nanoform establishes US subsidiary